Please use this identifier to cite or link to this item:
Title: Drug repurposing of Daclatasvir and Famciclovir as antivirals against dengue virus infection by in silico and in vitro techniques
Authors: P, Naresh
P, Shyam Sundar
K, Girija
SJ, Pradheesh
AG, Shanthoshivan
S, Akashwaran
AK, Swaroop
S, Jubie
Keywords: Dengue virus;Drug repurposing;Envelope protein;Hinge region;Molecular docking;n-Octyl-beta-Dglucopyranoside (βOG)
Issue Date: Dec-2021
Publisher: NIScPR-CSIR, India
Abstract: Drug repurposing is a technique for reusing an existing drug to treat another ailment. It is common knowledge that nearly all medicines used in human therapy have more than one target impact in addition to their primary action. The present work is aimed to repurpose existing antiviral drugs for dengue disease. A molecular docking study is performed with the DENVE protein for the identification of the suitable drug candidate which acts in the fusion process. For all repurposed drugs at the active site of DENVE, molecular docking experiments were performed using CLC Drug Discovery Workbench Software (PDB ID: 1OKE). The relative binding modes and the affinities of all the selected drugs were predicted and compared with the co-crystallized n-octyl-beta-D-glucopyranoside (βOG). The Daclatasvir (Score-53.52) makes hydrogen bonds with ALA50 and THY48. According to the docking score evaluation, the entire drug candidates had docking result ranging from −32.15 to −53.52. Among the drugs tested the two drugs namely Daclatasvir and Famciclovir have been identified as HITS for combating DENVE protein.
Page(s): 557-564
ISSN: 0975-0959 (Online); 0301-1208 (Print)
Appears in Collections:IJBB Vol.58(6) [December 2021]

Files in This Item:
File Description SizeFormat 
IJBB 58 (6) 557-564 Dec 2021.pdfMain Article563.81 kBAdobe PDFView/Open
IJBB 58 (6) 557-564 Dec 2021 Suppl. Table.pdfSuppl. Table1.23 MBAdobe PDFView/Open

Items in NOPR are protected by copyright, with all rights reserved, unless otherwise indicated.